New stock news | Cofoe Medical Technology plans to list in Hong Kong The China Securities Regulatory Commission requires clarification on whether the domestic subsidiary has violated regulations by issuing stocks overseas.

On October 24, the China Securities Regulatory Commission announced the requirements for supplementary materials for overseas issuance and listing filing disclosure (from October 20, 2025 to October 24, 2025). The CSRC requested Cofoe Medical Technology to further clarify whether its domestic subsidiaries are subject to the provisions of Article 8 of the Measures for the Administration of the Issuance and Listing of Securities by Domestic Enterprises Overseas prohibiting overseas issuance and listing. According to the disclosure on August 29 by the Hong Kong Stock Exchange, Cofoe Medical Technology submitted its listing application to the HKEx with Huatai International and BNP PARIBAS as joint sponsors. Furthermore, it was requested to provide supplementary information regarding the business scope of the issuer's subsidiaries including "advertising publication" and "advertising design, agency." They were asked to explain the progress of related businesses, if necessary qualifications and licenses have been obtained. Details were also sought on the development and operation of apps, mini-programs, WeChat official accounts, etc. by the issuer and its subsidiaries, and whether they involve the collection and use of personal information. If applicable, specify the scale of user information collection and storage, and data collection and usage. Regarding foreign investment access, explanations were required on: (1) the business scope of the issuer's subsidiaries including "internet information services," the progress of related businesses, and whether necessary qualifications and licenses have been obtained; (2) in addition to the above, whether the business scope and actual operations of the issuer and its subsidiaries involve any areas prohibited or restricted by the Negative List of Special Management Measures for Foreign Investment Access (2024 Edition). The prospectus indicates that Cofoe Medical Technology is one of the largest home medical equipment companies in China. According to Frost & Sullivan data, based on 2024 China sales, the company ranks second among all home medical equipment companies. During the past reporting period, Cofoe Medical Technology actively expanded into overseas markets, attracting an increasingly loyal global user base. Currently, Cofoe Medical Technology's global business footprint covers over 60 countries and regions in Asia, Africa, Europe, and the Americas. As of June 30, 2025, Cofoe Medical Technology owns 738 self-owned stores in China, with 689 of them being "Hearing Health" service centers, covering over 135 cities in China. The "Hearing Health" service centers provide professional hearing tests and supply various high-quality hearing aid products, including the self-owned Kofu brand. According to Frost & Sullivan data, as of the end of 2024, based on the number of hearing aid fitting centers in China, Hearing Health ranks among the top three in the industry.